37 results match your criteria: "The National Cancer Center Hospital[Affiliation]"
Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer.
N Engl J Med
November 2024
From Sorbonne Université, Hôpital Saint Antoine, Assistance Publique-Hôpitaux de Paris, Unité Mixte de Recherche Scientifique 938, and SIRIC CURAMUS, Paris (T.A.), Hopital Foch, Suresnes (J.B.), and Institut Paoli-Calmettes (C.F.), and La Timone, Aix Marseille Université (L.D.), Marseille - all in France; Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona (E.E.), Hospital Universitario Virgen del Rocío, Seville (M.L.L.), Institut Català d'Oncologia, Hospital Universitario Germans Trias i Pujol, Badalona (J.L.M.M.), and Hospital Universitario 12 de Octubre, Imas12, Medicine Department-UCM, Madrid (R.G.-C.) - all in Spain; University Hospitals Gasthuisberg and University of Leuven (KU Leuven), Leuven, Belgium (E.V.C.); the University Hospital of Southern Denmark, Vejle Hospital, Vejle (L.H.J.); Hospital Universitario Fundacion Favaloro, Buenos Aires (G.M.); Centrul de Oncologie Sf Nectarie, Craiova, Romania (M.S.); the National Cancer Center Hospital East, Chiba, Japan (T.Y.); Shanghai East Hospital, Shanghai, China (J.L.); the University of Southern California Norris Comprehensive Cancer Center, Los Angeles (H.-J.L.); Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome (G.T.), and Veneto Institute of Oncology IOV-IRCCS, Padua (S.L.) - both in Italy; the Netherlands Cancer Institute, Amsterdam (M.C.); Cancer Research SA, Adelaide, SA, Australia (R.J.); Hematology-Oncology Practice Eppendorf (HOPE) and University Cancer Center Hamburg (UCCH), Hamburg, Germany (E.G.); the Institute of Cancer of São Paulo, São Paulo (M.I.B.); Adana City Education and Research Hospital, Adana, Turkey (T. Cil); and Bristol Myers Squibb, Princeton, NJ (E.C., T. Chen, M.L., M.D., S.A.).
Background: Patients with microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) metastatic colorectal cancer have poor outcomes with standard chemotherapy with or without targeted therapies. Nivolumab plus ipilimumab has shown clinical benefit in nonrandomized studies of MSI-H or dMMR metastatic colorectal cancer.
Methods: In this phase 3 open-label trial, we randomly assigned patients with unresectable or metastatic colorectal cancer and MSI-H or dMMR status according to local testing to receive, in a 2:2:1 ratio, nivolumab plus ipilimumab, nivolumab alone, or chemotherapy with or without targeted therapies.
What Judith L. Johnson brought to us.
Asia Pac J Oncol Nurs
October 2024
Director of Nursing at the National Cancer Center Hospital in Japan, Certified Nurse in Cancer Pain Management, Japan.
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer.
N Engl J Med
July 2024
From Universitaire Ziekenhuizen Leuven, Katholieke Universiteit Leuven, and the Belgium and Luxembourg Gynaecological Oncology Group, Leuven (I.V., E.V.N.), and Centre Hospitalier Universitaire de Liège, Liege (C.G.) - all in Belgium; Cancer Center Clínica Universidad de Navarra (A.G.-M.), Hospital Universitario 12 de Octubre (L.M.), and Grupo Español de Investigación en Cáncer de Ovario (GEICO) (A.G.-M.), Madrid, and Gynecologic Cancer Program, Vall d'Hebron Institute of Oncology, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona (A.O.) - all in Spain; Saitama Medical School International Medical Center, Saitama (K.F., K.H.), and the National Cancer Center Hospital, Tokyo (K.Y.) - both in Japan; Centre Hospitalier Universitaire de Besançon, Besançon (E.K.), and GINECO (E.K., A.A.) and Groupe Hospitalier Diaconesses Croix Saint-Simon (A.A.), Paris - all in France; Országos Onkológiai Intézet, Budapest, Hungary (A.B.); Georgia Cancer Center, Augusta University, Augusta (S.G.); Yonsei University College of Medicine (J.-Y.L.) and Samsung Medical Center, Sungkyunkwan University School of Medicine (B.-G.K.) - both in Seoul, South Korea; the Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London (S.B.), and the Christie NHS Foundation Trust, Clinical Oncology, Manchester (L.B.) - both in the United Kingdom; Hospital Beneficencia Portuguesa de São Paulo (F.C.M.), Hospital Israelita Albert Einstein de São Paulo (F.C.M.), and Instituto Brasileiro de Controle do Câncer (F.M.C.) - all in Sao Paulo; Fondazione Policlinico Gemelli IRCCS and Catholic University of Sacred Heart, Rome (D.L.); Arbeitsgemeinschaft Gynäkologische Onkologie Study Group and University Medical Center Hamburg-Eppendorf, Hamburg, Germany (L.W.); Amsterdam University Medical Centers, Amsterdam (A.W.); Sunnybrook Research Institute, Toronto (A.C.); Medica Oncólogia Clinica en Grupo Gamma, Rosario, Argentina (M.R.); Skåne University Hospital and Lund University, Lund, Sweden (M.B.); First Faculty of Medicine, Charles University, General University Hospital in Prague, Prague, Czech Republic (D.C.); Pfizer, Bothell, WA (L.N., M.S.L.T., E.W.); Genmab US, Princeton, NJ (I.S.); and Mount Sinai Medical Center, Miami Beach, FL (B.M.S.).
Article Synopsis
- Recurrent cervical cancer poses serious health risks, especially after initial treatment, leading to the need for new therapy options.
- A phase 3 trial compared the effects of tisotumab vedotin to standard chemotherapy in 502 patients with recurrent or metastatic cervical cancer, focusing on overall survival.
- Results show that tisotumab vedotin significantly improved median overall survival (11.5 months vs. 9.5 months) and progression-free survival (4.2 months vs. 2.9 months), with a higher response rate compared to chemotherapy, despite both groups experiencing a high incidence of adverse events.
Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer: a plain language summary of the DESTINY-Gastric01 study.
Future Oncol
January 2024
Department of Gastrointestinal Oncology, The National Cancer Center Hospital East, Kashiwa, Japan.
What Is This Summary About?: This is a summary of the publication about the DESTINY-Gastric01 study, which was published in the in May 2020. The study included 187 adults in Japan and South Korea with gastric cancer or gastroesophageal junction cancer that had high levels of a protein called HER2 (HER2-positive). All the participants' cancer had spread to nearby or distant parts of the body and had worsened after receiving at least 2 previous cancer treatments or treatment combinations.
View Article and Find Full Text PDFPolatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.
N Engl J Med
January 2022
From the Department of Hematology and INSERM Unité 1245, Centre Henri-Becquerel and University of Rouen, Rouen (H.T.), Université de Lille, Centre Hospitalier Universitaire (CHU) Lille, ULR 7365 - GRITA - Groupe de Recherche sur les Formes Injectables et les Technologies Associées, Lille (F.M.), CHU de Montpellier, Montpellier (C.H.), the Department of Hematology, Institut Universitaire du Cancer, Toulouse-Oncopole, Toulouse (L.O.), and the Department of Hematology, Centre Hospitalier Régional Universitaire - Besançon, Besançon (A.C.) - all in France; the Centre for Lymphoid Cancer at BC Cancer and the University of British Columbia, Vancouver (L.H.S.), the Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto (M.C.C.), and F. Hoffmann-La Roche, Mississauga, ON (M.Y.) - all in Canada; the Wilmot Cancer Institute, University of Rochester, Rochester (J.W.F.), and Memorial Sloan Kettering Cancer Center, New York (M.M., G.S.) - both in New York; the First Faculty of Medicine, Charles University and the General University Hospital, Prague, Czech Republic (M.T.); the Willamette Valley Cancer Institute and Research Center, the US Oncology Network, Eugene, OR (J.P.S.); Rocky Mountain Cancer Centers, Aurora, CO (J.M.B.); Memorial Sloan Kettering Cancer Center, Montvale, NJ (M.M.); the Department of Hematology and Rheumatology, Kindai University, Faculty of Medicine, Osaka-Sayama City (S.R.), and the National Cancer Center Hospital, Tokyo (K.I.) - both in Japan; Washington University in St. Louis, St. Louis (N.M.-S.); the Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland (W.J.); Peking University Cancer Hospital, Beijing (Y.S.); the 3rd Medical Department, Paracelsus Medical University, Salzburg Cancer Research Institute-Center for Clinical Cancer and Immunology Trials, and Cancer Cluster Salzburg, Salzburg, Austria (R.G.); the Feofaniya Clinical Hospital, Kyiv, Ukraine (L.M.); Hospital San Pedro de Alcántara, Cáceres (J.M.B.-B.), and the Department of Hematology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona (P.A.) - both in Spain; the Hematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori, Fondazione G. Pascale, IRCCS, Naples, Italy (A.P.); the Division of Hematology-Oncology, Department of Internal Medicine, Research Institute of Medical Science, Pusan National University Hospital, Pusan National University School of Medicine, Busan, South Korea (H.-J.S.); Princess Alexandra Hospital, Brisbane, QLD, Australia (G.H.); Hospital Erasto Gaertner, Curitiba, Brazil (E.M.); Taipei Veterans General Hospital, Taipei, Taiwan (J.-P.G.); Genentech, South San Francisco, CA (J.H., Y.J., C.L.); and M.D. Anderson Cancer Center, Houston (C.R.F.).
Article Synopsis
- Diffuse large B-cell lymphoma (DLBCL) is commonly treated with a regimen called R-CHOP, but only about 60% of patients are cured.
- A clinical trial tested a modified treatment called pola-R-CHP, substituting vincristine with polatuzumab vedotin.
- Results showed that patients treated with pola-R-CHP had significantly better progression-free survival rates compared to those on standard R-CHOP, although overall survival rates were similar in both groups.
Impact of a web-based educational program on Japanese nurses tobacco cessation practice and attitudes in oncology settings.
J Nurs Scholarsh
May 2022
Social Behavioral Sciences, School of Nursing, University of California San Francisco, San Francisco, USA.
Purpose: To evaluate the effects of a short web-based educational program on Japanese nurses' self-reported attitudes toward tobacco cessation and their use of interventions to help smokers to quit.
Design: Prospective, single-group design with a pre-educational survey, a short web-based educational program, and a follow-up survey at 3 months.
Methods: Clinical nurses were asked to view two prerecorded webcasts about helping smokers quit.
Trastuzumab Deruxtecan in -Mutant Non-Small-Cell Lung Cancer.
N Engl J Med
January 2022
From Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York (B.T.L.); the Netherlands Cancer Institute, Amsterdam (E.F.S); the National Cancer Center Hospital, Tokyo (Y.G.), Kindai University Hospital, Osaka (K.N.), and the National Cancer Center East, Kashiwa (H.U.) - all in Japan; Centre Hospitalier Universitaire, Toulouse (J.M.), Centre Léon Bérard, Lyon (M.P.), and the Department of Medical Oncology, Thoracic Group, Gustave Roussy, Villejuif (D.P.) - all in France; Karmanos Cancer Institute, Detroit (M.N.); the University of California, San Diego, Moores Cancer Center, San Diego (L.B.); Moffitt Cancer Center, Tampa, FL (A.N.S.); Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona (E.F.); University of Colorado, Aurora (J.M.P.); Hospital Universitario 12 de Octubre, H12O-Centro Nacional de Investigaciones Oncológicas (CNIO) Lung Cancer Clinical Research Unit, and Complutense University, Madrid (L.P.-A.); Daiichi Sankyo, Basking Ridge, NJ (K.S., R.S., Y.C., S.A., P.V., J.S.); and Dana-Farber Cancer Institute and the Belfer Center for Applied Cancer Science, Boston (P.A.J.).
Article Synopsis
- - A phase 2 study tested trastuzumab deruxtecan, a HER2-targeted therapy, in patients with metastatic non-small-cell lung cancer (NSCLC) who were unresponsive to standard treatments, focusing on its efficacy and safety.
- - Out of 91 patients, 55% showed an objective response to the treatment, with a median response duration of 9.3 months and overall survival of 17.8 months; however, severe adverse effects occurred in 46% of participants.
- - The study found effective responses across various mutation subtypes and in some patients without detectable HER2 alterations, but also highlighted serious safety concerns, including fatal cases of interstitial lung disease.
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.
N Engl J Med
June 2020
From the National Cancer Center Hospital East, Kashiwa (K. Shitara), the National Cancer Center Hospital (S.I.), Daiichi Sankyo (T.K., A.K., M.S.), and the Cancer Institute Hospital of JFCR (K.Y.), Tokyo, the Osaka International Cancer Institute (N.S.), Osaka University Hospital (D.S.), and Kindai University Hospital (H.K.), Osaka, and Niigata Cancer Center Hospital, Niigata (H.Y.) - all in Japan; Seoul National University College of Medicine (Y.-J.B.), the Asan Medical Center, University of Ulsan College of Medicine (M.-H.R.), the Yonsei Cancer Center, Yonsei University College of Medicine (H.-C.C.), and the Samsung Medical Center, Sungkyunkwan University School of Medicine (J.L.) - all in Seoul, South Korea; and Daiichi Sankyo, Basking Ridge, NJ (K. Saito, Y.K.).
Background: Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate consisting of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor. The drug may have efficacy in patients with HER2-positive advanced gastric cancer.
Methods: In an open-label, randomized, phase 2 trial, we evaluated trastuzumab deruxtecan as compared with chemotherapy in patients with HER2-positive advanced gastric cancer.
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.
N Engl J Med
December 2019
From the South Australian Health and Medical Research Institute and the University of Adelaide, Adelaide, SA, Australia (T.P.H., D.Y., D.M.R.); Memorial Sloan Kettering Cancer Center, New York (M.J.M., M.S.T., J.H.P.); University of Texas M.D. Anderson Cancer Center, Houston (J.E.C.); Kobe University Graduate School of Medicine, Kobe (H.M.), and the National Cancer Center Hospital East, Chiba (Y.M.) - both in Japan; Hôpital Saint-Louis, Paris (D.R.), and the University of Bordeaux, Bordeaux (F.-X.M.) - both in France; Dana-Farber Cancer Institute, Boston (D.J.D.); Sapienza University, Rome (M.B.); Singapore General Hospital, Singapore (Y.-T.G.); University of Michigan Comprehensive Cancer Center, Ann Arbor (M.T.); Universitätsklinikum Jena, Jena (A.H.), Charité Hospital, Berlin (P.C.), and the Department for Hematology-Oncology, Goethe University Hospital, Frankfurt am Main (F.L.) - all in Germany; University of Cardiff, Cardiff, United Kingdom (O.O.); Veterans Affairs Portland Health Care System (M.C.H.) and Oregon Health and Science University Knight Cancer Institute (M.C.H., B.J.D.), Portland; Hospital de la Princesa and Instituto de Investigación Sanitaria Princesa, Madrid (J.L.S.); Huntsman Cancer Institute, University of Utah, Salt Lake City (M.W.N.D.); Amsterdam University Medical Centers, VU University Medical Center, Amsterdam (J.J.W.M.J.); Novartis Pharma, Basel, Switzerland (D.H., Y.D., C.M., F.H.-P., K.G.V.); and Seoul St. Mary's Hematology Hospital, Catholic University of Korea, Seoul, South Korea (D.-W.K.).
Background: Asciminib is an allosteric inhibitor that binds a myristoyl site of the BCR-ABL1 protein, locking BCR-ABL1 into an inactive conformation through a mechanism distinct from those for all other ABL kinase inhibitors. Asciminib targets both native and mutated BCR-ABL1, including the gatekeeper T315I mutant. The safety and antileukemic activity of asciminib in patients with Philadelphia chromosome-positive leukemia are unknown.
View Article and Find Full Text PDFJapan NBI Expert Team classification: Narrow-band imaging magnifying endoscopic classification of colorectal tumors.
Dig Endosc
July 2018
Endoscopy Division, the National Cancer Center Hospital, Tokyo, Japan.
Multi-institutional comparison of computer-based independent dose calculation for intensity modulated radiation therapy and volumetric modulated arc therapy.
Phys Med
January 2018
Particle Therapy Division, Exploratory Oncology Research and Clinical Trial Center, The National Cancer Center Hospital East, Chiba 2778577, Japan. Electronic address:
Article Synopsis
- A multi-institutional study was conducted to assess the discrepancies between radiotherapy treatment planning systems (TPSs) and verification programs for IMRT and VMAT.
- The analysis involved 477 IMRT/VMAT plans, revealing that the sliding window technique had greater negative systematic differences compared to the step-and-shoot technique, and that head and neck plans showed larger dose variations than prostate plans.
- The findings suggest that a local dose difference of ±5% may be a reasonable benchmark for institutions when evaluating agreement between primary calculations and verification for these radiation therapies.
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.
N Engl J Med
November 2017
From New York University Perlmutter Cancer Center, New York (J.W.); Papa Giovanni XXIII Cancer Center Hospital, Bergamo (M. Mandala), Medical Oncology, National Cancer Institute, Milan (M.D.V.), Oncology Institute of Veneto Istituti di Ricovero e Cura a Carattere Scientifico, Padua (V.C.-S.), Center for Immuno-Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena (M. Maio), Ospedale Policlinico San Martino, Genoa (P.Q.), and Istituto Nazionale Tumori Fondazione Pascale, Naples (P.A.A.) - all in Italy; National and Kapodistrian University of Athens, Athens (H.J.G.); Hospital Clinic de Barcelona, Barcelona (A.M.A.), and General University Hospital Gregorio Marañón, Madrid (I.M.-R.) - both in Spain; Texas Oncology-Baylor Cancer Center, Dallas (C.L.C.); Hospices Civils de Lyon, Pierre Bénite (S.D.), Aix-Marseille University, Hospital de la Timone, Marseille (J.-J.G.), Institut Universitaire du Cancer de Toulouse and Centre Hospitalier Universitaire (CHU), Toulouse (N.M.), Université Lille, INSERM Unité 1189, CHU Lille, Lille (L.M.), and Assistance Publique-Hôpitaux de Paris, Dermatology and Centres d'Investigation Clinique, INSERM Unité 976, Hôpital Saint Louis, Université Paris Diderot, Paris (C.L.) - all in France; Oncology Center Sf. Nectarie, Craiova, Romania (M. Schenker); Princess Margaret Cancer Centre, University of Toronto, Toronto (M.O.B.), and Cross Cancer Institute, Edmonton, AB (M. Smylie) - both in Canada; the Department of Oncology, University of Oxford, Oxford (M.R.M.), and Royal Marsden NHS Foundation Trust, London (J.L.) - both in the United Kingdom; Gallipoli Medical Research Foundation and University of Queensland, Queensland, VIC (V.A.), and Melanoma Institute Australia, University of Sydney, and Royal North Shore and Mater Hospitals, Sydney (G.V.L.) - all in Australia; University of Colorado, Denver (R.G.); Winship Cancer Institute, Emory University School of Medicine, Atlanta (R.R.K.); Georgetown-Lombardi Comprehensive Cancer Center, Washington DC (M.B.A.); University of Washington, Seattle (S.B.); Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland (P.R.); Nagoya University Graduate School of Medicine, Nagoya (K.Y.), and the National Cancer Center Hospital, Tokyo (N.Y.) - both in Japan; Seoul National University Hospital, Seoul, South Korea (T.M.K.); and Bristol-Myers Squibb, Princeton, NJ (V.P, J.S., A.Q.).
Background: Nivolumab and ipilimumab are immune checkpoint inhibitors that have been approved for the treatment of advanced melanoma. In the United States, ipilimumab has also been approved as adjuvant therapy for melanoma on the basis of recurrence-free and overall survival rates that were higher than those with placebo in a phase 3 trial. We wanted to determine the efficacy of nivolumab versus ipilimumab for adjuvant therapy in patients with resected advanced melanoma.
View Article and Find Full Text PDFComprehensive technical and patient-care optimization in the management of pediatric apheresis for peripheral blood stem cell harvesting.
Transfus Apher Sci
December 2016
Department of Pediatric Oncology, Fukushima Medical University, Fukushima, Japan.
Article Synopsis
- Pediatric apheresis for stem cell transplantation is risky due to factors like low blood volume and potential complications like hypocalcemia and shock.
- A study of 267 procedures on 93 children showed a median yield of CD34+ cells, with adverse events occurring in 11.6% of cases, primarily mild.
- Implementing safety measures improved outcomes significantly, reducing complications from 16.4% to 5.8% over different study periods, especially benefiting children under 10 kg.
Erratum to: Current status of development of anticancer agents in Japan.
Int J Hematol
June 2008
Division of Exploratory Research, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.
Characterization of acute graft-versus-host disease following reduced-intensity stem-cell transplantation from an HLA-identical related donor.
Am J Hematol
August 2008
Hematopoietic Stem Cell Transplantation Unit, The National Cancer Center Hospital, Tokyo, Japan.
To investigate clinical features of acute graft-versus-host disease (GVHD) following reduced intensity stem-cell transplantation (RIST), we retrospectively investigated medical records of 65 patients with hematologic malignancies who underwent RIST from a matched related donor. Preparative regimen comprised fludarabine 30 mg/m(2) (n = 53) or cladribine 0.11 mg/kg (n = 12) for 6 days plus busulfan 4 mg/kg for 2 days.
View Article and Find Full Text PDFCurrent status of development of anticancer agents in Japan.
Int J Hematol
June 2008
Division of Exploratory Research, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.
To investigate the current status of the development of anticancer agents in Japan, we examined the number of these agents developed after 1999, their target diseases, and the association between the number of approved agents and the number of patients with the diseases. The data were obtained via the Internet. Of the 487 agents approved from 1999 to April 2007, 84 were anticancer drugs.
View Article and Find Full Text PDFComparison between reduced intensity and conventional myeloablative allogeneic stem-cell transplantation in patients with hematologic malignancies aged between 50 and 59 years.
Bone Marrow Transplant
October 2005
Hematopoietic Stem Cell Transplantation Unit, the National Cancer Center Hospital, and Department of Cell Therapy & Transplantation Medicine, University of Tokyo, Japan.
To evaluate the efficacy of reduced-intensity stem-cell transplantation (RIST), we retrospectively compared outcomes of 207 consecutive Japanese patients aged between 50 and 59 years with hematologic malignancies who received RIST (n=70) and conventional stem-cell transplantation (CST) (n=137). CST recipients received total body irradiation (TBI)-based or busulfan/cyclophosphamide-based regimens. RIST regimens were purine analog-based (n=67), 2 Gy TBI-based (n=2), and others (n=1).
View Article and Find Full Text PDFEarly immune reaction after reduced-intensity cord-blood transplantation for adult patients.
Transplantation
July 2005
Hematopoietic Stem-cell Transplantation Unit, the National Cancer Center Hospital, Tokyo, Japan.
Background: To investigate immune reactions after reduced-intensity cord-blood transplantation (RI-CBT).
Materials And Methods: We reviewed medical records of 57 adult RI-CBT recipients. Preparative regimen comprised fludarabine, total-body irradiation, and either melphalan (n=51) or busulfan (n=6).
Chest computed tomography of late invasive aspergillosis after allogeneic hematopoietic stem cell transplantation.
Biol Blood Marrow Transplant
July 2005
Hematopoietic Stem Cell Transplantation Unit, The National Cancer Center Hospital, Tokyo, Japan.
Computed tomography (CT) is a powerful diagnostic tool for invasive aspergillosis (IA) after allogeneic stem cell transplantation (allo-SCT); however, little information is available concerning CT findings of late IA after allo-SCT. To characterize CT findings of late IA, we retrospectively examined medical records and high-resolution CT findings of 27 allo-SCT recipients with late IA. Either acute or chronic GVHD was diagnosed in 24 patients.
View Article and Find Full Text PDFOptimal initial dose of oral cyclosporine in relation to its toxicities for graft-versus-host disease prophylaxis following reduced-intensity stem cell transplantation in Japanese patients.
Bone Marrow Transplant
June 2005
Haematopoietic Stem Cell Transplantation Unit, the National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
Since the introduction of reduced-intensity stem-cell transplantation (RIST), allogeneic stem-cell transplantation has become available for elderly patients. While pharmacokinetics of cyclosporine might differ according to age or other factors, cyclosporine is uniformly started at an oral dose of 6 mg/kg/day. We retrospectively reviewed medical records of 35 patients aged between 32 and 65 (median 52) years who had undergone RIST.
View Article and Find Full Text PDFDeep lamellar keratoplasty for corneal perforation due to chronic graft-versus-host disease following allogeneic hematopoietic stem-cell transplantation.
Haematologica
March 2005
Hematopoietic Stem Cell Transplantation Unit, the National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
Value of surveillance blood culture for early diagnosis of occult bacteremia in patients on corticosteroid therapy following allogeneic hematopoietic stem cell transplantation.
Bone Marrow Transplant
March 2005
Hematopoietic Stem Cell Transplantation Unit, The National Cancer Center Hospital, Japan.
Bloodstream infection (BSI) is a significant complication following allogeneic hematopoietic stem cell transplantation (allo-SCT). Corticosteroids mask inflammatory responses, delaying the initiation of antibiotics. We reviewed medical records of 69 allo-SCT patients who had been on >0.
View Article and Find Full Text PDFFulminant septicemia caused by Bacillus cereus following reduced-intensity umbilical cord blood transplantation.
Haematologica
January 2005
Hematopoietic Stem Cell Transplantation Unit, the National Cancer Center Hospital, Tokyo, Japan.
Reduced-intensity hematopoietic stem cell transplantation (RIST) for solid malignancies.
Jpn J Clin Oncol
December 2004
Department of Medical Oncology, Hematopoietic Stem Cell Transplantation Unit, the National Cancer Center Hospital, Chuo-ku, Tokyo 104-0045, Japan.
Reduced intensity stem cell transplantation (RIST) is a new approach of stem cell transplantation, which has shown promising features as reported in multiple phase I and II studies. Elderly patients, who are not eligible for conventional myeloablative hematopoietic stem cell transplantation (HSCT), are now treatable with RIST. It has also reduced regimen-related toxicity and provided better prognosis in short-term follow-up than conventional HSCT.
View Article and Find Full Text PDFReduced-intensity allogeneic hematopoietic stem-cell transplantation as an immunotherapy for metastatic colorectal cancer.
Transplantation
December 2004
Hematopoietic Stem Cell Transplant Unit, the National Cancer Center Hospital, Tokyo, Japan.
Background: Allogeneic stem-cell transplantation (allo-SCT) can induce curative graft-versus-leukemia reactions for hematologic malignancies through allogeneic immunity. Because the gastrointestinal tract is a target of graft-versus-host disease (GvHD), colorectal cancer might be a candidate for allo-SCT.
Methods: Four patients with metastatic colorectal cancer underwent reduced-intensity stem-cell transplantation (RIST) in the National Cancer Center Hospital between July 2002 and February 2003.